Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Green Mountain Coffee Slips Lower After T2’s Tilson Comments on SEC Probe

Green Mountain Coffee Roasters (GMCR) has had a rough October. The coffee giant popular for its Keurig K-Cups has fallen almost 30% since October 1, 2011. It went from trading at $92.94 a share to $65.44 at close October 27, 2011.

T2 PARTNERS

It Started at the Value Investing Congress

David Einhorn gave a speech denouncing the coffee company on October 17Einhorn criticized GMCR for its “poor transparency,” “accounting discrepancies,” confusing quarterly financial presentations and June quarterly results that look “too good to be true.” He also said that “capital spending is growing much faster than the business,” adding, “management has been incredibly vague about where the money is going.” Prior to Einhorn’s comments, GMCR stock was solidly above $92 a share. The share price fell over 24% in the first days after the speech ($92.09 to $69.80) and just continued downward.

Then There was Tilson

On October 26, GMCR shares slid even lower after Whitney Tilson, founding and managing director of the hedge fund T2 Partners, “told CNBC there may be potential for accounting fraud at the company,” reports Bloomberg. The shares fell another 4.9% to settle at $61.59, its lowest since March 21. Specifically, Bloomberg writes that Tilson said of the SEC probe against GMCR, “We think that they are going to find something.” Tilson also said that his fund was shorting the stock.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!